Want to see HK:6609 full AI Analyst Report?
6609 Stock Chart & Stats
HK$54.60
-HK$0.05(-0.24%)
At close: 4:00 PM EST
HK$54.60
-HK$0.05(-0.24%)
Day’s Range― - ―
52-Week RangeHK$35.00 - HK$71.25
Previous CloseN/A
Volume1.35K
Average Volume (3M)33.16K
Market Cap
HK$2.16B
Enterprise ValueHK$664.27
Total Cash (Recent Filing)HK$789.70M
Total Debt (Recent Filing)HK$41.22M
Price to Earnings (P/E)18.2
Beta1.47
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.48
Shares Outstanding31,565,804
10 Day Avg. Volume42,082
30 Day Avg. Volume33,155
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.61
Price to Sales (P/S)4.47
P/FCF Ratio13.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.91
Revenue Forecast (FY)HK$546.64M
Bulls Say, Bears Say
Bulls Say
Strong Revenue ExpansionThe substantial increase in revenue indicates that the company has expanded its commercial scale and customer reach over several years. A larger revenue base can improve operating leverage, support investment in medical-device capabilities, and strengthen the platform for future growth.
Improved Profitability And MarginsThe return to positive operating and net profit, alongside a high gross margin, shows that the enlarged business can generate meaningful earnings when revenue scales. If maintained, this profitability can fund development internally and improve resilience without relying as heavily on external capital.
Low Leverage And Stronger Cash GenerationVery low leverage preserves financial flexibility, while the shift to positive operating and free cash flow demonstrates improved cash conversion in 2025. Together, these features give the company greater capacity to fund operations, absorb volatility, and support measured reinvestment.
Bears Say
Profitability Durability Remains UnprovenThe recent earnings inflection is encouraging, but it has not yet been demonstrated across a sustained period. Multiple earlier loss-making years, including 2024, make it uncertain whether the new margin profile reflects durable operating performance or a still-unproven stage of business development.
Volatile Cash-flow HistoryPositive cash flow in 2025 materially improves the outlook, but the preceding negative years show that cash generation has not been stable across periods. Continued variability could constrain internally funded investment and make planning less predictable if operating performance weakens.
Historical Losses Pressured ReturnsAlthough returns became positive in 2025, prior losses reduced the consistency of shareholder returns and required the equity base to absorb weak performance. Ongoing reinvestment needs may keep returns uneven until the company proves that growth can be sustained with dependable profitability.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H News
6609 FAQ
What was Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price range in the past 12 months?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H lowest stock price was HK$35.00 and its highest was HK$71.25 in the past 12 months.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap is HK$2.16B.
When is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 186 days.
How were Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s earnings last quarter?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H released its earnings results on Aug 31, 2026. The company reported HK$1.869 earnings per share for the quarter.
Is Shanghai Heartcare Medical Technology Corp. Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price is currently Overvalued.
Does Shanghai Heartcare Medical Technology Corp. Ltd. Class H pay dividends?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H does not currently pay dividends.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Heartcare Medical Technology Corp. Ltd. Class H have?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H has 31,565,804 shares outstanding.
What happened to Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price movement after its last earnings report?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H reported an EPS of HK$1.869 in its last earnings report. Following the earnings report the stock price went up 2.653%.
Which hedge fund is a major shareholder of Shanghai Heartcare Medical Technology Corp. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6609
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
Shanghai HeartCare Medical Technology Corporation Limited is a global enterprise specializing in the research, development, manufacturing, and commercialization of neuro-interventional medical devices. Its extensive product range encompasses devices for ischemic stroke thrombectomy, intracranial stenosis intervention, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access. These medical technologies are utilized for both the prevention and treatment of ischemic stroke, including acute ischemic events and intracranial narrowing, as well as for addressing hemorrhagic stroke. Established in 2016 and previously operating as Shanghai Care Medical Technology Corporation Limited, the company maintains its headquarters in Shanghai, People's Republic of China.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) Earnings & Revenues
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
MicroPort CardioFlow Medtech Corp.
―
Venus Medtech (Hangzhou), Inc. Class H
―